PDCD1 and Hodgkins lymphoma: The most promising immunotherapeutic approach involves antibodies targeting the immune checkpoint inhibitor (ICI) molecules, as demonstrated in Hodgkin’s lymphoma in which programmed death 1 (PD-1, CD279) receptor blockage resulted in response rate of 87%, probably based on the molecular upregulation of PD-1 and its ligands (PD-Ls) pathways (6, 7).